Bractoppin is a combination of human breast and ovarian cancer suppressor protein (BRCA1) by tandem BRCT (tandem BRCT, BRCA1). The tBRCT domain recognizes drug-like inhibitors of phosphopeptide and selectively inhibits binding of nanomolar substrates in vitro with an IC50 of 0.074 μM.

 

Brand: BCM

 

Target: Others; DNA/RNA Synthesis

 

Signaling Pathways: Cell Cycle/Checkpoint; DNA Damage/DNA Repair; Others

 

Boiling Poing: 625.7±65.0 °C(Predicted)

 

pKa: 10.70±0.10(Predicted)

 

Isomeric SMILES: C1CN(CCN1CC2=CC=CC=C2F)C(=O)C3=CC4=C(C=C3)N=C(N4)C5=CC=CC=C5  

InChIKey: UHDGSNOZRAAGIZ-UHFFFAOYSA-N  

 

InChI: InChI=1S/C25H23FN4O/c26-21-9-5-4-8-20(21)17-29-12-14-30(15-13-29)25(31)19-10-11-22-23(16-19)28-24(27-22)18-6-2-1-3-7-18/h1-11,16H,12-15,17H2,(H,27,28)

 

Attribute
[Chem Name]	[4-[(2-fluorophenyl)methyl]piperazin-1-yl]-(2-phenyl-3H-benzimidazol-5-yl)methanone
[Synonym]	Bractoppin
[CAS No.]	2290527-07-8
[MDL No.]	MFCD33402156
[Formula]	C25H23FN4O
[Molecular]	414.47
[Form]	Solid Powder
[Storage]	Sealed in dry, 2-8°C

Goods Tag